Success For Current COVID-19 Development Programs
Our teams are currently supporting over a dozen COVID-19 trials for vaccines, antivirals, antiseptic, and treatments for cytokine storm syndrome. Our very first milestone for the COVID-19 pandemic response took place on 24 March 2020, we helped a sponsor get their database live for a phase I COVID-19 vaccine trial in 10 business days so they could begin patient enrollment immediately. We repeated this success for multiple other studies. Additionally, we have established a cross-functional COVID-19 task force that meets weekly to share knowledge, the challenges and solutions that our programs are facing, such as how Remdesivir is affecting antiviral trials or how patients are being followed up if they are released from the hospital days earlier than planned.
Learn more about this and other key lessons learned and strategies for success in conducting COVID-19 programs:
- Read our blog post on Clinical Trial Conduct Lessons Learned in Month 1 of COVID-19 Response
- Read our success guide on COVID-19 Key Strategies for Success
- Download our case study Rapid Launch of a COVID-19 Phase I Vaccine Trial
- Read the blog post by one of our partners- IBM | The search for life sciences solutions to the COVID-19 crisis
Explore some of our additional relevant knowledge:
- Download our case study Rapid Response to Ebola Outbreak
- Explore our Infectious Disease Expertise from over 160 trials
- Read about our Skilled Vaccine Development Expertise
Let Us Help You Maintain Trial Integrity
We understand that the stakes are high no matter where you are in your development program. The stress, anxiety, and uncertainty about ongoing, new, or COVID-19-related clinical programs is overwhelming. We have the agility and scientific-minded experts to help you navigate these uncertain times.
Schedule an introduction by completing the form below:
